In a report released yesterday, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on CTI BioPharma (CTIC), with a price target of $7.80. The company’s shares closed last Wednesday at $3.30.
According to TipRanks.com, Cann is a 4-star analyst with an average return of 12.5% and a 50.4% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Syros Pharmaceuticals, and X4 Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CTI BioPharma with a $7.80 average price target.
See today’s analyst top recommended stocks >>
CTI BioPharma’s market cap is currently $247.5M and has a P/E ratio of -4.90. The company has a Price to Book ratio of 5.32.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
